Products Eptinezumab is in the development phase and is not yet commercially available. Structure and properties Eptinezumab is an IgG1 monoclonal antibody directed against CGRP. Effects Eptinezumab reduces the number of migraine attacks. The effects are due to binding of the antibody to CGRP, the calcitonin gene-related peptide. CGRP is a neuropeptide that plays an … Eptinezumab
Products Basiliximab is commercially available as an injectable (Simulect, Novartis). It has been approved in many countries, in the EU, and in the United States since 1998. Structure and properties Basiliximab is a chimeric monoclonal human murine IgG1κ antibody with a molecular mass of 144 kDa. It is produced by biotechnological methods. The drug name … Basiliximab
Symptoms Melanomas are discolored, growing, skin lesions that arise from pigmented moles in about 30% of cases. They are found primarily on the skin, but can occur anywhere melanocytes are found, including the oral mucosa, respiratory tract, or eye, for example. In men they are most common on the upper body, in women on the … Melanoma Causes and Treatment
Products Tocilizumab is commercially available as a concentrate for the preparation of an infusion solution and as a solution for injection in a prefilled syringe and in a prefilled pen (Actemra, RoActemra in some countries). It has been approved in many countries since 2008. Structure and properties Tocilizumab is a recombinant humanized IgG1 monoclonal antibody … Tocilizumab
Products Adalimumab is commercially available as a solution for injection (Humira). It was approved in the United States in 2002 and in many countries and the EU in 2003. Biosimilars are available in many countries. Structure and properties Adalimumab is a human IgG1 monoclonal antibody against TNF-alpha. It is composed of 1330 amino acids and … Adalimumab Effects and Side Effects
Products The first therapeutic monoclonal antibody was approved in 1986. Muromonab-CD3 (Orthoclone OKT3) binds to the CD3 receptor on T cells and has been used in transplantation medicine. Numerous drugs containing antibodies are now available. A selection of active substances can be found at the end of this article. These are expensive drugs. For example, … Monoclonal Antibodies
Products Therapeutic proteins are usually administered in the form of injection and infusion preparations and must be stored in a refrigerator. The first recombinant protein to be approved was human insulin in 1982. Some proteins, for example, are also available in tablet, capsule, and powder form and can be stored at room temperature, such as … Therapeutic Proteins
Products Panitumumab is commercially available as an infusion solution (Vectibix). It has been approved in many countries since 2008. Structure and properties Panitumumab is a recombinant, fully human IgG2 monoclonal antibody against EGFR. Effects Panitumumab (ATC L01XC08) has antitumor and antiangiogenic properties. The effects are due to binding to the epidermal growth factor receptor (EGFR). … Panitumumab
Products Romosozumab was approved for injection in the United States and EU in 2019 and in many countries in 2020 (Evenity). Structure and properties Romosozumab is a humanized Ig2 monoclonal antibody with a molecular mass of 149 kDa produced by biotechnological methods. Effects Romosozumab (ATC M05BX06) promotes bone formation and, to a lesser extent, additionally … Romosozumab
Definition Active ingredients are the active components of a drug that are responsible for its pharmacological effects. Drugs may contain a single active ingredient, multiple active ingredients, or complex mixtures such as herbal extracts. In addition to the active ingredients, a drug contains various excipients that should be as pharmacologically inert as possible. The percentage … Pharmaceutical Active Ingredient
Products Tildrakizumab was approved as an injectable in the United States and EU in 2018 and in many countries in 2019 (ilumetri). Structure and properties Tildrakizumab is a humanized IgG1/k monoclonal antibody with an approximate molecular mass of 147 kDa. It is produced by biotechnological methods. Effects Tildrakizumab (ATC L04AC17) has immunosuppressive and anti-inflammatory properties. … Tildrakizumab
Products Belimumab is commercially available as a powder for the preparation of an infusion solution concentrate. It was approved in the EU in 2011 and in many countries in 2012 (Benlysta). In 2018, a solution for subcutaneous injection was registered (autoinjector and prefilled syringe). Structure and properties Belimumab is a human IgG1λ monoclonal antibody with … Belimumab